Telix Pharmaceuticals (TLX) News Today

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares have declined amid fresh regulatory hurdles, litigation risks, and downward earnings revisions, partially offset by a bullish price target from Wedbush.

• Positive Sentiment: Wedbush reaffirmed its "Outperform" rating on TLX and kept a $22.00 price target—implying over 130% upside. Wedbush Rating
• Neutral Sentiment: JPMorgan Chase & Co. reiterated its "Neutral" rating on TLX, maintaining its view amid volatility. JPMorgan Neutral Rating
• Negative Sentiment: The FDA has requested more data on TLX’s kidney cancer diagnostic drug and the SEC issued a subpoena, triggering a roughly 16% drop in shares. TLX Hits Another Roadblock After SEC Subpoena
• Negative Sentiment: Pomerantz LLP launched an investor class action inquiry into TLX, highlighting potential shareholder lawsuits. Investor Alert: Pomerantz Investigates
• Negative Sentiment: Investors sold off TLX after a third U.S. regulatory setback, with the FDA again seeking additional data on its cancer diagnostic candidate. Health Check: Angry Investors Birch TLX Shares
• Negative Sentiment: Wedbush cut a host of TLX earnings estimates—trimming forecasts for FY2025–27 and quarterly EPS from Q1 2026 through Q2 2027—though it kept its Outperform stance and $22 target. Wedbush Cuts Earnings Estimates
• Negative Sentiment: William Blair lowered its FY2027 EPS forecast for TLX to $0.44 from $0.49, dialing back growth expectations. William Blair Lowers FY2027 EPS